Asset icon - trade crypto, stocks, and gold on Pluang
Trade on Pluang
One platform for all markets
Download
Investment
Features
FeesSafety
Academy
More
Pluang+

TREMFYA shows superior fistula remission in Crohn's disease at Week 24, first major progress in 20 years.

Market News
05 May 2026
PRNewsWire
View Source
Bullish
pluang ai news

Johnson & Johnson's TREMFYA (guselkumab) demonstrated significantly higher combined fistula remission rates in adults with perianal fistulizing Crohn's disease at Week 24 compared to placebo in the Phase 3 FUZION study. This marks the first randomized controlled trial in 20 years to show efficacy for this challenging Crohn's disease complication, offering hope for improved management of a debilitating condition. The study's positive results support TREMFYA as a new treatment option, with ongoing research including a head-to-head trial against another IL-23 inhibitor underway.

More News (JNJ)

banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App